Advisory Panel to Review Bayer Drug
Federal Register notice: FDA has announced an 11/16 Antimicrobial Drugs Advisory Committee meeting that will review a Bayer NDA for ciprofloxacin inhalation powder, indicated for reducing exacerbations in non-cystic fibrosis bronchiectasis adult patients with respiratory bacterial pathogens. To view the notice, click here.